Halda reports positive prostate cancer candidate results
PHOTOS | Michelle Tuccitto Sullo
Craig Crews, center, prepares to cut the ceremonial ribbon in front of Halda Therapeutics’ new home in Winchester Works in 2021.
New Haven biotech company Halda Therapeutics on Tuesday announced positive results in preclinical trials of its oral candidate for the treatment of prostate cancer.
The company plans to present its data at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, which is taking place in San Francisco from Feb. 16-18.
According to Halda, its therapeutic demonstrated tumor growth inhibition in castrated mice and showed in vitro anti-cancer cell activity.
Halda is developing a novel class of cancer therapies called RIPTAC (Regulated Induced Proximity TArgeting Chimeras) therapeutics. It works as a novel “hold and kill” mechanism for the precision treatment of cancer, according to the company.
Halda, located in Winchester Works, has raised $76 million to date from investors, including Canaan Partners, Access Biotechnology, Elm Street Ventures and Connecticut Innovations.
Halda has used the money to create a platform and pipeline of small molecule, anti-cancer drug candidates.
Yale University professor Craig Crews, Halda’s scientific founder, said, “This modality offers an oral, selective, and widely applicable cancer cell-killing mechanism that can overcome drug resistance and can be used in advanced cancer where resistance has emerged, as well as potentially in early-stage cancer.”
Kat Kayser-Bricker, chief scientific officer at Halda, said the company is excited to unveil the first data for its lead pipeline candidate.
“Novel drug mechanisms are desperately needed to better address prostate cancer and the emergence of resistance to standard of care,” Kayser-Bricker said.
An estimated 1 in 8 men will be diagnosed with prostate cancer in his lifetime, and about 1 man in 41 will die of the disease, according to the American Cancer Society.
Contact Michelle Tuccitto Sullo at msullo@newhavenbiz.com.
Most Recent
Most Recent
0 Comments